Trial Profile
A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Ianalumab (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 09 Nov 2021 Results assessing possible options for alternative responder definitions that indicate the optimal balance of sensitivity and specificity from dour trials ((NCT02962895, NCT02775916; NCT02291029; NCT02149420) presented at the ACR Convergence 2021
- 02 Mar 2019 Efficay and safety results published in the Annals of the Rheumatic Diseases
- 02 Apr 2018 Status changed from active, no longer recruiting to completed.